Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (June 2024)
28 slides from Transgene Sa's investor presentation, Jun 3, 2024
Slide 1: Unlocking the Full Potential of the Immune System Against Cancer
Unlocking the Full Potential of the Immune System Against Cancer Corporate Presentation June 3, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Transgene
Transgene Innovative Clinical-Stage Click to edit Master title style Immunotherapy Portfolio Based on Viral Vectors Cutting-edge Additional individualized neoantigen immuno-oncology programs cancer vaccine (TG4050) with clinical proof of principle Significant • Proof of principle obtained in • Share
Slide 4: TG4050 – A Novel Individualized Cancer Immunotherapy
TG4050 – A Novel Individualized Cancer Immunotherapy Click to edit Master title style MVA VECTOR BENEFITS THE RIGHT NEOANTIGENS INDICATION Induces broad and specific immune Comprises up to 30 neoantigens Targeting head and neck patients – response – Almost all patients treated selected using NEC’s a
Slide 5: Our Pipeline – Poised to Deliver Important Data in 2024
Our Pipeline – Poised to Deliver Important Data in 2024 Click to edit Master title style Product Indication Collaboration Discovery Phase I Phase II Key upcoming catalysts INDIVIDUALIZED NEOANTIGEN CANCER VACCINES Head and neck 24-month median follow up on Phase I part (H2 2024) TG4050 cancer (adjuv
Slide 6: Cancer Therapeutic Vaccines
Cancer Therapeutic Vaccines Focused on delivering the promise of individualized cancer vaccine
Slide 7: myvac® - TG4050 | Combines Unique Know How and Expertise
myvac® - TG4050 | Combines Unique Know How and Expertise Click to edit Master title style MVA viral vector: a powerful Artificial Intelligence to identify platform for vaccine development up to 30 potent neoantigens Strongly immunogenic vector o NEC’s machine learning environment based on o Demonstr
Slide 8: TG4050 | Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy
TG4050 | Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy Click to edit Master title style Ongoing Phase I/II trial Approx. 80 patients with locoregionally advanced HPV-negative SCCHN** (NCT: 04183166) TG4050 Need to prevent or delay relapse (single agent) Repeated injections Clinical
Slide 9: TG4050 | Generates and/or Expands Tumor Specific T Cells
TG4050 | Generates and/or Expands Tumor Specific T Cells Click to edit Master title style Number of positive responses per patients Head and neck cancer trial Despite low mutational burden, De novo responses Amplified responses immunogenic targets could be selected Stable responses* # of neoantigens
Slide 10: TG4050 | Persistent Specific Cellular Response Following Vaccination
TG4050 | Persistent Specific Cellular Response Following Vaccination Click to edit Master title style Patients display persistent specific CD8+ responses against multiple selected targets, 7 months after treatment induction Source: A. Lalanne et al., “Personalized vaccine TG4050 induces polyepitopic
Slide 11: Promising Signals of Clinical Activity in Adjuvant Setting
Promising Signals of Clinical Activity in Adjuvant Setting Click to edit Master title style Head & Neck Cancer Trial No related SAEs 32 patients randomized – March 2024 Good safety profile 6 months 12 months 18 months 24 months 30 months 36 months Median follow up of 18.6 months Arm A: TG4050 single
Slide 12: TG4050 | Additional Data in 2024
TG4050 | Additional Data in 2024 Click to edit Master title style one patient • one genome • one vaccine 24-month median follow up expected in H2 2024 on Phase I part (32 patients) Signs Excellent of clinical safety Ongoing Phase II part – Last patient to be enrolled benefit profile in H2 2025 Induc
Slide 13: TG4001 | Ongoing Proof of Concept Trial to Read out in H2 2024
TG4001 | Ongoing Proof of Concept Trial to Read out in H2 2024 Click to edit Master title style Topline data expected Ongoing Phase II trial in patients with HPV16+ anogenital cancer in H2 2024 incl. cervical, vulvar, vaginal, penile and anal cancers NCT: 03260023 • To deliver PoC data in significan
Slide 14: Oncolytic Viruses
Oncolytic Viruses Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors
Slide 15: Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation
Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Click to edit Master Data Support Intravenous (IV) Route of Administration title style Patented Backbone VVcopTK-RR- vector with multiple Cancer cell death through multiple MOAs competitive ad
Slide 16: TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor
TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor Ongoing Click to edit Phase I Trial Master title style to Assess Systemic Route of Administration Oncolytic armed with IL-12 and anti-CTLA4 Ab • Triggers a powerful antitumor immune response • Restores the immune defenses w
Slide 17: BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF
BT-001 | OV Armed with Anti-CTLA4 Ab + GM-CSF 50/50 collaboration with BioInvent Ongoing Click to edit Phase I Trial Master title style Assessing IT* Route of Administration The right virus + payload Positive Phase I part A readout VVcopTK-RR- oncolytic armed with BioInvent’s potent anti-CTLA4 Ab +
Slide 18: Outlook
Outlook transgene
Slide 19: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Ownership FINANCIAL VISIBILITY As of September 30, 2023 secured until Q4 2025 Enables Transgene to deliver significant milestones including key PoC data for TG4050 and data on all assets 60% Free float 40% • Listed on Euronext Paris • IS
Slide 20: 2024 Anticipated Value Creating News
2024 Anticipated Value Creating News Click to edit Master title style TG4050 | Neoantigen vaccine Shared antigens cancer vaccines TG4001: Results from ongoing randomized Phase II Proof of principle (H2 2024) already obtained in Head and Neck cancer (adjuvant) ➔ Strong immunogenicity, persistent cell
Slide 21: Investment Highlights
Investment Highlights Click to edit Master title style Lead program TG4050 Additional programs Unique and highly to deliver data in 2024 and R&I activity to potent and create significant deliver news flow and viral vector based value fuel Transgene’s immunotherapies by 2026 portfolio in the mid term
Slide 22: Appendices
Ccpemecrane Appendices
Slide 23: New Leadership to Take Transgene to the Next Level
New Leadership to Take Transgene to the Next Level Click to edit Master title style ÉRIC QUÉMÉNEUR, MAUD BRANDELY, MD, ALESSANDRO RIVA, MD Chairman & CEO PharmD, PhD - Executive PhD - VP, Medical Affairs VP - Chief Scientific Officer - Chief Medical Officer 30+ years experience LUCIE LARGUIER JAMES
Slide 24: Viral Vaccines Prime Both Long Lasting Innate and Adaptive Immunity
Viral Vaccines Prime Both Long Lasting Innate and Adaptive Immunity Click to edit Master title style Post-exposure time Few hours – few days (<48h) Few days Few Weeks Few Months Granulocytes Dendritic cells CD8+ T cells Macrophages CD4+ T cells B cells Plasma cells Antibodies Innate immunity NK cell
Slide 25: TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation STANDARD DATA PROCESSING, ROUTINE GENE/EXOME ARTIFICIAL GMP TREATMENT TUMOR BIOPSY SEQUENCING INTELLIGENCE GENE EDITING MANUFACTURING ADMINIS
Slide 26: Exploration of Tumor TME
Exploration of Tumor TME Challenging population with high prevalence of low/negative TME: tumor micro-environment, TMB: tumor mutational burden, PD-L1 expressors and relatively poor pro-immune infiltrates F:Click to edit fibrotic, Master title style NF: non-fibrotic Arm A: TG4050 single agent Arm B:
Slide 27: Profound Remodelling of Immune Cells Consistent with Anti Tumor Response
Profound Remodelling of Immune Cells Consistent with Anti Tumor Response Suggests that the Click to edit Master Vaccine Effectively Primes the Immune System title style neg aiveNaive in CD4 in CD4 Naive in CD8b Naive % CD16 in in CD56dim CD8b Memory in CD4 NKMemory in CD4 Memory in CD8b Effector in
Slide 28: Contact
C O N TA C T Lucie Larguier Chief Financial Officer +33 6 7624 7227 larguier@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr 28